$LLY

AI Analysis

Generated on May 18, 2026

AI Score
77/ 100
Buy$LLY

Eli Lilly and Company

$LLYNYSEHealthcareMega-Cap

Eli Lilly discovers, develops, and markets pharmaceutical products for endocrinology, oncology, and immunology worldwide.

Market Cap
$850B
Revenue (TTM)
$48.5B
+32.8%
Net Income (TTM)
$12.8B
+45.5%
EPS (TTM)
$14.25
P/E Ratio
62.5
Dividend Yield
0.6%
52-Week Range
$680-$980
Beta
0.42
Dimension Scores
Fundamental
80
Technical
72
Sentiment
80
Risk / Reward
74
Momentum
70
FundTechSentRiskMome
Financial Health
Profitability
82strong
Growth
92strong
Liquidity
78moderate
Solvency
70moderate
Efficiency
75moderate

Valuation, technical analysis, investment thesis, risk assessment and more for $LLY

Free · No credit card required

Disclaimer: AI-generated analysis for educational purposes only. Not financial advice. Always consult a qualified financial advisor.

Explore more

Analyze any stock with AI

Get a structured equity research report covering fundamentals, technicals, sentiment, risk, and investment thesis — in about 60 seconds.